Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis.

Kanokwan PinyopornpanishWael Al-YamanRobert S ButlerWilliam CareyArthur McCulloughCarlos Romero-Marrero

Published in: The American journal of gastroenterology (2021)

Our findings suggest that patients with NASH and bridging fibrosis have a low risk of HCC. Dose-dependent statin use reduced HCC risk significantly in patients with NASH cirrhosis.

Keyphrases

cardiovascular disease
coronary artery disease
low density lipoprotein
liver fibrosis